Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Mahmud, E; Schmid, F; Kalmar, P; Deutschmann, H; Hafner, F; Rief, P; Brodmann, M.
Feasibility and Safety of Robotic Peripheral Vascular Interventions: Results of the RAPID Trial.
JACC Cardiovasc Interv. 2016; 9(19):2058-2064
Doi: 10.1016/j.jcin.2016.07.002
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Brodmann Marianne
- Deutschmann Hannes
- Hafner Franz
- Kalmar Peter
- Rief Peter
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- The goal of this study was to evaluate the feasibility and safety of a robotic-assisted platform (CorPath 200, Corindus Vascular Robotics, Waltham, Massachusetts) for treating peripheral artery disease. A robotic-assisted platform for percutaneous coronary intervention is available for treating coronary artery disease. In this prospective single-arm trial, patients with symptomatic peripheral artery disease (Rutherford class 2 to 5) affecting the femoropoplital artery were enrolled. Endpoints evaluated were: 1) device technical success, defined as successful cannulation of the target vessel with the robotic system; 2) device safety, defined as absence of device related serious adverse event (hospitalization, prolonged hospitalization, life threatening, or resulted in death); and 3) clinical procedural success, defined as <50% residual stenosis without an unplanned switch to manual assistance or device-related serious adverse event in the periprocedural period. The study enrolled 20 subjects (65.5 ± 9.3 years of age; 70% male) with primarily Rutherford class 2 to 3 (90%) symptoms. A total of 29 lesions (lesion length: 33.1 ± 15.5 mm) were treated with the majority (89.7%) being located in the superficial femoral artery. Device technical success, safety and clinical procedural success were all 100% with provisional stenting required in 34.5% of lesions. Fluoroscopy time (7.1 ± 3.2 min) and contrast use (73.3 ± 9.2 ml) compared favorably with studies in similar patient cohorts. There were no adverse events associated with the use of the robotic system. These data demonstrate the feasibility and safety of using a robotic-assisted platform for performing peripheral arterial revascularization. Copyright © 2016 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
- Find related publications in this database (using NLM MeSH Indexing)
- Aged -
- Austria -
- Constriction, Pathologic -
- Contrast Media - administration & dosage
- Feasibility Studies -
- Female -
- Femoral Artery - diagnostic imaging
- Femoral Artery - physiopathology
- Femoral Artery - surgery
- Humans -
- Length of Stay -
- Male -
- Middle Aged -
- Operative Time -
- Peripheral Arterial Disease - diagnostic imaging
- Peripheral Arterial Disease - physiopathology
- Peripheral Arterial Disease - surgery
- Popliteal Artery - diagnostic imaging
- Popliteal Artery - physiopathology
- Popliteal Artery - surgery
- Postoperative Complications - etiology
- Prospective Studies -
- Radiography, Interventional -
- Robotic Surgical Procedures - adverse effects
- Robotic Surgical Procedures - instrumentation
- Stents -
- Time Factors -
- Treatment Outcome -
- Vascular Patency -
- Vascular Surgical Procedures - adverse effects
- Vascular Surgical Procedures - instrumentation
- Vascular Surgical Procedures - methods
- Find related publications in this database (Keywords)
- interventions
- peripheral artery disease
- PVI
- robotic assisted